SGLT2 Inhibitors in Clinical Practice

Mechanism of Action and Classification

• The American Journal of Kidney Diseases notes that SGLT2 inhibitors like Farxiga work by inhibiting glucose reabsorption in the kidneys, leading to increased urinary glucose excretion, and are classified as sodium-glucose cotransporter-2 inhibitors 1, 2
• SGLT2 inhibitors primarily target glucose reabsorption in the proximal renal tubules, unlike traditional diuretics that directly target sodium and water reabsorption 3

Diuretic-Like Effects and Clinical Considerations

• The European Journal of Heart Failure recommends that SGLT2 inhibitors like Farxiga can mitigate fluid retention, which can be beneficial in patients with heart failure or volume overload 1, 2
• The American Journal of Kidney Diseases suggests that when initiating Farxiga, healthcare providers may need to reduce doses of traditional diuretics in patients at risk for hypovolemia or hypotension 1
• The European Journal of Heart Failure notes that SGLT2 inhibitors like Farxiga offer long-term kidney protection and can cause a mild and transient drop in estimated glomerular filtration rate (eGFR) soon after treatment initiation 2

Indications and Usage

• The American College of Cardiology recommends SGLT2 inhibitors as core treatments for heart failure with reduced ejection fraction (HFrEF), alongside ACE inhibitors/ARBs, beta-blockers, and mineralocorticoid receptor antagonists 6, 7
• The European Journal of Heart Failure notes that Farxiga can be used at eGFR ≥20 mL/min/1.73 m² for heart failure and chronic kidney disease benefits, though its glucose-lowering effect diminishes at lower eGFR levels 5

Distinguishing Features from Traditional Diuretics

• The European Journal of Heart Failure notes that traditional diuretics directly target different segments of the nephron to increase water and sodium excretion, whereas SGLT2 inhibitors have demonstrated cardioprotective and renoprotective effects independent of their diuretic action 2, 5
• The European Journal of Heart Failure suggests that when SGLT2 inhibitors are used in combination with mineralocorticoid receptor antagonists, they may reduce the risk of hyperkalemia, facilitating the use of these agents together 2

Safety Considerations

• The Diabetes Care journal notes that Farxiga has a low risk of hypoglycemia when used alone or with metformin, though risk varies depending on background therapy 8